Humacyte, Inc. (HUMA): Nasdaq/NYSE listing notice — Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply

Humacyte, Inc.

Received Nasdaq letter on May 4, 2026, for bid price below $1.00 for 30 consecutive business days through May 1, 2026.
Must regain compliance by Nov 2, 2026, by having closing bid price ≥ $1.00 for at least 10 consecutive business days.
No immediate effect on listing; common stock continues to trade on Nasdaq under symbol HUMA.
Company intends to monitor bid price and evaluate available options to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Humacyte, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, th

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-057974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.